Roche's new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer

Subcutaneous formulation is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form; Herceptin is used to treat more than 80,000 patients each year in Europe
Source: Roche Media News - Category: Pharmaceuticals Source Type: news